VERTEX PHARMACEUTICALS INC (VRTX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for VRTX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| VRTX | Executive Vice President, Chief Operating and Financial Officer | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| TJX | Executive Vice President and Chief Operating & Financial Officer | 58 | ["Executive Vice President and Chief Operating & Financial Officer of Vertex Pharmaceuticals, Inc. (2025 to current)","Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, Inc. (2019 to 2025)","Executive Vice President, Finance and Chief Financial Officer at Ortho Clinical Diagnostics (2015 to 2019)","Executive Vice President, Finance & Administration and Chief Financial Officer, Bruker Corporation (2012 to 2015)","Executive Vice President, Finance & Administration and Chief Financial Officer, Progress Software (2010 to 2012)","Vice President and Chief Financial Officer, Millipore Corporation (2002 to 2010)","Various senior financial roles at Bain & Company and Coopers & Lybrand (1990 to 2002)"] | ["Audit and Finance Committee"] | 2026 |
| BRKR | Director | 44 | ["Former Executive Vice President of Finance and Administration and Chief Financial Officer of Progress Software Corporation","Experience at Millipore Corporation in various roles including Vice President and Chief Financial Officer","Financial expert on the Company's Audit Committee","B.S. from Boston College and M.B.A. from Harvard Business School","Considerable financial and management experience with publicly-traded companies"] | ["Audit Committee"] | 2012 |